Development of a rheumatology-specific patient concerns inventory and its use in the rheumatology outpatient clinic setting

…, D Lowe, JA Kirton, MR O'Brien, A Mediana… - The Journal of …, 2016 - jrheum.org
Objective. Successful management of rheumatic conditions involves increasing complexity
of care. Delivering this in a holistic way is a growing challenge. The aim of our study was to …

Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence

AL Cross, J Hawkes, H Frankland, A Mediana… - …, 2023 - academic.oup.com
Objectives Identifying that dysfunction of the IL-23/17 axis underlies PsA has led to the
development of effective targeted therapies such as the IL-17A inhibitor secukinumab. As IL-17A …

AB0115 SECUKINUMAB THERAPY DOES NOT AFFECT NEUTROPHIL HOST DEFENCE IN PSORIATIC ARTHRITIS

A Cross, J Hawkes, H Frankland, A Mediana, H Wright… - 2020 - ard.bmj.com
Background: Biologic therapies have revolutionised therapy in inflammatory diseases such
as psoriatic arthritis (PsA), driving major improvements in outcomes. Th17 cells appear to …

AB0116 Decreased Serum Level of Irisin in Patients With Ankylosing Spondylitis

B Nam, S Jo, S Lee, TH Kim - 2020 - ard.bmj.com
Background: Irisin, exercise-mediated myokine, is one of the most recently discovered
hormones. Irisin has been shown to play multifunctional roles including anti-inflammation by …

[HTML][HTML] Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis

S Zhao, B Challoner, M Khattak, RJ Moots… - Rheumatology …, 2017 - Springer
… We thank research nurses Helen Frankland and Ayren Mediana for their help in recruiting
patients and collecting data. We also thank Stephen Duffield for proofreading and helpful …

[HTML][HTML] Autoantibodies to osteoprotegerin are associated with low hip bone mineral density and history of fractures in axial spondyloarthritis: a cross-sectional …

B Hauser, S Zhao, MR Visconti, PL Riches… - Calcified Tissue …, 2017 - Springer
… We thank research nurses Helen Frankland and Ayren Mediana for recruiting patients. We
also thank laboratory scientists Dr Andrew Cross and Jenny Hawkes for technical assistance. …

A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment

JC Davies, E Carlsson, A Midgley, EMD Smith… - …, 2021 - academic.oup.com
Objectives ∼30% of patients with SLE develop LN. Presence and/or severity of LN are
currently assessed by renal biopsy, but biomarkers in serum or urine samples may provide an …

Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's …

A Dumusc, WF Ng, K James, B Griffiths… - Swiss medical …, 2018 - nrl.northumbria.ac.uk
OBJECTIVES: To assess the use of the Clinical EULAR Sjogren's Syndrome Disease Activity
Index (ClinESSDAI), a version of the ESSDAI without the biological domain, for assessing …

[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods This …

[HTML][HTML] Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its
immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in …